Anonymous 14/02/15
Last reply 3 years ago
GILENYA – NO COMPELLING PML EVIDENCE

Sept ’14 BOSTON — A new report describes cases of progressive multifocal leukoencephalopathy (PML) that have been seen to date among patients with multiple sclerosis (MS) treated with fingolimod (Gilenya, Novartis Pharma AG), all but 1 of whom had previously been treated with natalizumab (Tysabri, Biogen Idec), known to carry a risk for PML.

The lingering question is whether there is any risk for PML with the new oral agent, but the authors suggest that the 1 patient not previously treated with natalizumab may have had neuromyelitis optica (NMO) rather than MS, and had several atypical features.

Tysabri does not clear the system for up to 6 months, authors report.

Read the entire article at: http://www.medscape.com/viewarticle/832307

Add categories

Browse categories and add by clicking on them

You can remove current categories below by clicking the ‘x’.

Post Comment

You must be logged in to reply to this topic.